VONVENDI / VEYVONDI (Recombinant von Willebrand Factor)

VONVENDI (marketed as VEYVONDI in the EU), from Takeda, is a recombinant von Willebrand factor (vonicog alfa) indicated for the treatment and control of bleeding episodes, and for perioperative management of bleeding, in adults and adolescents with von Willebrand disease (VWD).

It replaces the deficient or defective von Willebrand factor in VWD patients, restoring the protein’s normal function in platelet adhesion and stabilizing clotting factor VIII in the bloodstream, helping to control and prevent bleeding episodes.

• Thrombotic events have been reported, particularly when used with factor VIII or in patients with known risk factors for thrombosis.
• Hypersensitivity reactions, including anaphylaxis, may occur.
• Neutralizing antibodies (inhibitors) to von Willebrand factor may develop; monitor for reduced clinical response.
• Regular monitoring of von Willebrand factor and factor VIII levels is recommended during treatment.

What documents are required to import VONVENDI/VEYVONDI to India?

It may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered hematologist
• Diagnostic report confirming von Willebrand disease diagnosis and type
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is it available in India?

VONVENDI/VEYVONDI is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source VONVENDI/VEYVONDI from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA (as VONVENDI) — December 2015.
• European Union: Approved by the EMA (as VEYVONDI) — August 2018.

What is VONVENDI/VEYVONDI used for?

It treats and controls bleeding episodes and manages perioperative bleeding in patients with von Willebrand disease.

Who manufactures it?

It is developed by Takeda, marketed as VONVENDI in the US and VEYVONDI in the EU.

How is it administered?

By intravenous infusion, dosed based on the patient’s weight and bleeding severity.

How much does it cost in India?

Cost depends on dose and treatment duration — share your prescription with IPN for a quote.